Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Psychopharmacology (Berl) ; 237(11): 3225-3236, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32651640

ABSTRACT

The asymptomatic and clinical stages of Parkinson's disease (PD) are associated with comorbid non-motor symptoms including gastrointestinal (GI) dysfunction. Although the neuroprotective and gastroprotective roles of kolaviron (KV) have been reported independently, whether KV-mediated GI-protective capacity could be beneficial in PD is unknown. We therefore investigated the modulatory effects of KV on the loss of dopaminergic neurons, locomotor abnormalities, and ileal oxidative damage when rats are lesioned in the nigrostriatal pathway. KV treatment markedly suppressed the behavioral deficit and apomorphine-induced rotations associated with rotenone lesioning. KV attenuated the loss of nigrostriatal dopaminergic neurons and perturbations in the striatal glucose-regulated protein (GRP78) and X-box binding protein 1 (XBP1) levels. Ileal epithelial injury following stereotaxic rotenone infusion was associated with oxidative stress and marked inhibition of acetylcholine esterase activity and reduced expression of occludin in the crypt and villi. While KV treatment attenuated the redox imbalance in the gut and enhanced occludin immunoreactivity, acetylcholinesterase activity was not affected. Our data demonstrate ileal oxidative damage as a characteristic non-motor gut dysfunction in PD while showing the potential dual efficacy of KV in the attenuation of both neural defects and gut abnormalities associated with PD.


Subject(s)
Corpus Striatum/drug effects , Flavonoids/administration & dosage , Gastrointestinal Microbiome/drug effects , Parkinsonian Disorders/prevention & control , Rotenone/toxicity , Substantia Nigra/drug effects , Animals , Corpus Striatum/metabolism , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/metabolism , Flavonoids/isolation & purification , Gastrointestinal Microbiome/physiology , Male , Nerve Degeneration/chemically induced , Nerve Degeneration/drug therapy , Nerve Degeneration/prevention & control , Neuroprotective Agents/administration & dosage , Parkinsonian Disorders/chemically induced , Parkinsonian Disorders/metabolism , Plant Extracts/administration & dosage , Plant Extracts/isolation & purification , Rats , Rotenone/administration & dosage , Stereotaxic Techniques , Substantia Nigra/metabolism
2.
Environ Toxicol Pharmacol ; 78: 103412, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32439558

ABSTRACT

Although sexual health is affected by Parkinson's disease (PD), the effect on testicular health and/or sperm quality is not well discussed. After 21 days of rotenone lesioning, we observed dopaminergic neuronal degeneration in the substantia nigra and hypothalamus. There were minimal SPACA-1-expressing epididymal spermatozoa with morphological abnormalities, scanty luminal spermatozoa and reduced testicular spermatids and post-meiotic germ cells indicating hypospermatogenesis. Occludin-expressing sertoli cells were dispersed over a wide area indicating compromised blood-testes barrier. Activated caspase-3 expression was intense while immunoreactivity of spermatogenic-enhancing SRY and GADD45 g was weak. Although serum follicle stimulating hormone level was not affected, the lesion was associated with reduced serum testosterone level, testicular oxidative damage and inhibition of acetylcholinesterase activity, even when rotenone was not detected in the testes. Together, dopaminergic lesions may mediate testicular and sperm abnormalities via the brain-hypothalamic-testicular circuit independent of the pituitary, thereby establishing a causal link between Parkinsonism and reproductive dysfunction.


Subject(s)
Dopaminergic Neurons/pathology , Parkinson Disease, Secondary/pathology , Substantia Nigra/pathology , Testis/pathology , Ventral Tegmental Area/pathology , Acetylcholinesterase/metabolism , Animals , Dopaminergic Neurons/drug effects , Male , Parkinson Disease, Secondary/chemically induced , Parkinson Disease, Secondary/metabolism , Rats , Rotenone , Spermatozoa/drug effects , Substantia Nigra/drug effects , Testis/drug effects , Testis/metabolism , Ventral Tegmental Area/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL